NasdaqGS:GHHealthcare
What Guardant Health (GH)'s New HER2-Positive NSCLC Companion Dx Approval Means For Shareholders
Earlier in June 2026, Guardant Health announced that the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS, the first targeted therapy for adults with HER2-mutant advanced non-small cell lung cancer as an initial treatment option.
This 27th companion diagnostic indication extends Guardant360 CDx across more tumor types and leverages its broad payer coverage of more than 300 million lives, potentially reinforcing its role in...